Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2

Figure 1 Effect of DHDMBF30 against the Capan-2 cell proliferation of human pancreatic cancer.

Figure 2 Apoptosis rate of Capan-2 cells. A: Before the treatment of DHDMBF30; B: After the treatment of DHDMBF30.

Figure 3 Observation by electron microscope. A: Before the treatment of DHDMBF30 on Capan-2 cells; B: After the treatment of DHDMBF30 on Capan-2 cells.

Figure 4 The effect of DHDMBF30 against different mRNA. A: Against 5-LOX mRNA and COX-2-mRNA in Capan2 cells. Lane 1: COX-2 after inhibition; Lane 2: 5-LOX after inhibition; Lane 3: 5-LOX before inhibition; Lane 4: COX-2 before inhibition; Lane 5: β-actin; Lane 6: Marker; B: Against VEGF mRNA in Capan2 cells. Lane 1: Control group; Lane 2: Treatment group; Lane 3: β-actin; Lane 4: Marker; C: Against the VEGF mRNA of transplant pancreatic tumor cell in the hairless mice. Lane 1: Treatment group; Lane 2: Control group; Lane 3: β-actin; Lane 4: Marker.

Figure 5 The VEGF expression of different group. A: Control group; B: DHDMBF30 group.